EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lonza Group's Enterprise Value is $43,192 Mil.
Lonza Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $997 Mil. Therefore, Lonza Group's EV-to-EBIT for today is 43.32.
The historical rank and industry rank for Lonza Group's EV-to-EBIT or its related term are showing as below:
LZAGY'
s EV-to-EBIT Range Over the Past 10 Years
Min: 15.77 Med: 32.58 Max: 70.36
Current: 43.37
During the past 13 years, the highest EV-to-EBIT of Lonza Group was 70.36. The lowest was 15.77. And the median was 32.58.
LZAGY's EV-to-EBIT is ranked worse than 81.31% of 107
companies
in the Medical Diagnostics & Research industry
Industry Median: 19.67
vs LZAGY: 43.37
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Lonza Group's Enterprise Value for the quarter that ended in Dec. 2023 was $32,116 Mil.
Lonza Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $997 Mil. Lonza Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.10%.
Lonza Group EV-to-EBIT Historical Data
The historical data trend for Lonza Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Lonza Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group EV-to-EBIT Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lonza Group's EV-to-EBIT falls into.
Lonza Group EV-to-EBIT Calculation
Lonza Group's EV-to-EBIT for today is calculated as:
Lonza Group's current Enterprise Value is $43,192 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lonza Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $997 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (OTCPK:LZAGY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lonza Group's Enterprise Value for the quarter that ended in Dec. 2023 was $32,116 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lonza Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $997 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Lonza Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LZAGY has been successfully added to your 